Temazolamide and irinotecan for Ewing’s Sarcoma – pro
Preclinical models show sequence-dependent synergy with temozolomide and irinotecan in Ewing’s sarcoma. A retrospective 2009 review found that shows activity in highly refractory ES. Home administration was safe and is reasonable for palliative care, which is a significant advantage. Despite fairly limited evidence to support this regimen, ESMO says: “Chemotherapy regimens in relapse situations are not standardized and are commonly based on alkylating agents (cyclophosphamide, ifosfamide) in combination with topoisomerase inhibitors (etoposide, topotecan) or irinotecan with temozolomide [III, B].” On p. Bone-C, 1 NCCN also recommends this regimen for relapsed Ewing.
NCCN lists also chemo: ICE, IE, docetaxel/gemcitaibne, cyclophosphamide and topotecan.
Casey DA, Wexler LH, Merchant MS, Chou AJ, Merola PR, Price AP, Meyers PA.
Irinotecan and temozolomide for Ewing sarcoma: the Memorial Sloan-Kettering experience.
Pediatr Blood Cancer. 2009 Dec; 53(6):1029-34
L. M. Wagner, N. McAllister, A. Rausen, B. McCarville, R. Goldsby, K. Albritton Temozolomide and Intravenous Irinotecan for Refractory Ewing’s Sarcoma: A Retrospective Review Journal of Clinical Oncology, 2005 ASCO Annual Meeting Proceedings. Vol 23, No. 16S, Part I of II (June 1 Supplement), 2005: 8526 and Pediatr Blood Cancer. 2007 Feb;48(2):132-9.
M. Paulussen, S. Bielack, H. Jürgens, P. G. Casali and On behalf of the ESMO Ewing’s sarcoma of the bone: ESMO Clinical Recommendations for diagnosis, treatment and follow-up Ann Oncol (2009) 20 (suppl 4): iv140-iv142.
Casey DA, Wexler LH, Merchant MS, Chou AJ, Merola PR, Price AP, Meyers PA.
Irinotecan and temozolomide for Ewing sarcoma: the Memorial Sloan-Kettering experience.
Pediatr Blood Cancer. 2009 Dec; 53(6):1029-34
L. M. Wagner, N. McAllister, A. Rausen, B. McCarville, R. Goldsby, K. Albritton Temozolomide and Intravenous Irinotecan for Refractory Ewing’s Sarcoma: A Retrospective Review Journal of Clinical Oncology, 2005 ASCO Annual Meeting Proceedings. Vol 23, No. 16S, Part I of II (June 1 Supplement), 2005: 8526 and Pediatr Blood Cancer. 2007 Feb;48(2):132-9.
M. Paulussen, S. Bielack, H. Jürgens, P. G. Casali and On behalf of the ESMO Ewing’s sarcoma of the bone: ESMO Clinical Recommendations for diagnosis, treatment and follow-up Ann Oncol (2009) 20 (suppl 4): iv140-iv142.